Rare MET gene mutation linked to fatty liver disease

Mayo Clinic researchers have pinpointed a rare mutation in the MET gene that directly causes metabolic dysfunction-associated steatotic liver disease (MASLD). The discovery emerged from a father and daughter who developed the disease despite lacking common risk factors like obesity or diabetes. The mutation impairs the liver’s ability to process fat, leading to inflammation, scarring, and potentially irreversible cirrhosis. While the initial case involved just two individuals, large-scale genomic data suggests similar rare variants may contribute to MASLD in a far larger, undiagnosed population ScienceDaily.

The MET gene, previously linked to cancer signaling, is now implicated in a metabolic disorder that affects up to 30% of adults globally. Unlike typical MASLD cases driven by lifestyle factors, this genetic variant operates through a distinct biological pathway. The finding underscores how rare mutations can quietly drive widespread disease, particularly in patients with no obvious red flags. However, the study’s small sample size—limited to a single family—raises questions about its broader applicability. Further research is needed to determine how common this variant is in the general population.

For patients, the discovery offers a potential explanation for unexplained liver disease but does not yet translate to new treatments. Current management of MASLD remains focused on lifestyle modifications, even as this genetic insight opens avenues for targeted therapies. The regulatory pipeline for such treatments is lengthy, with no immediate changes to clinical guidelines expected.

This study falls under the category of observational research, meaning it identifies a correlation but cannot prove causation on a population level. The father-daughter case provides a compelling genetic link, yet larger studies are required to confirm whether the MET mutation is a primary driver or one of many contributors to MASLD. The Mayo Clinic team analyzed genomic data from thousands of individuals, but the variant’s rarity means its true prevalence remains uncertain. Without broader validation, clinicians cannot yet use this finding to screen or diagnose patients.

What this discovery does change, however, is the conversation around MASLD’s hidden causes. For decades, the disease was primarily attributed to metabolic syndrome, alcohol use, or viral hepatitis. The identification of a genetic mutation challenges that assumption, suggesting that some cases may have roots in DNA rather than behavior. This shift could influence future research directions, including efforts to develop gene-specific therapies or diagnostic tools. Still, the path from genetic discovery to clinical application is measured in years, if not decades.

The real bottleneck here is not the science but the scale. With only a handful of confirmed cases, researchers must now expand their search to see if the MET mutation appears in other MASLD patients without traditional risk factors. If confirmed, it could redefine how the medical community understands—and treats—a disease that currently affects millions. Until then, this remains an intriguing but early-stage finding, one that highlights the complexity of liver disease and the gaps in our current knowledge.